This biotech company's promising pipeline could result in multibillion-dollar revenue. "Buy when there's blood in the streets," was something famous banker Baron Rothschild once advised, suggesting the time to invest is when everyone else is fleeing a particular asset or the market in general. And superstar investor Cathie Wood did just that last week when she added to her holding of Moderna (MRNA -8.06%), buying shares for both her flagship Ark Innovation fund and her Ark Genomic Revolution fund. Moderna s ...